Abstract:Choroidal neovascularization (CNV) is one of the severe pathological consequences of the end-stage of age-related macular degeneration (AMD). Several lines of evidence implicate increased levels of vascular endothelial growth factor (VEGF) in the retinas of AMD patients. Current available agents for the inhibition of VEGF protein such as bevacizumab show significant promise for the treatment of exudative AMD. However, this compound still has limited efficacy and requires multiple administrations; thus, it is associated with a variety of ocular complications, including endophthalmitis and retinal detachment. In this study, we used anti-VEGFA/VEGFR2 or non-specific siRNA and evaluated their suppression of laser-induced choroidal neovascularization (CNV) in mice. Male adult C57BL/6J mice were used in the study. The mice were subjected to laser rupture of Bruch's membrane to induce CNV and then randomized to five groups with six mice per group. The five groups were blank control, vehicle control (5% glucose solution, GS), VEGFA.siRNA, VEGFR2.siRNA, and non-specific siRNA. Two days after laser photocoagulation, each group, with the exception of the blank control group, received 1 microl of the appropriate agent by intravitreal injection to both eyes. Seven days later, after taking fundus photography and fundus fluorescein angiography (FFA), the mice were killed for tissue sampling. Six eyes from three mice in each group were used for choroidal flatmounts to examine CNV. Six eyes from three mice in each group were subjected to RNA extraction for VEGF mRNA quantification by qRT-PCR. Retinal tissue from 2 mice without laser treatment was harvested as the assay reference. The incidence of burns which showed fluorescein leakage was 80.0% in blank control, 75.0% in GS, 55.0% in VEGFA.siRNA, 40.0% in VEGFR2.siRNA and 30.0% in non-specific siRNA group. The flatmounted specimens showed that the retinal pigment epithelium (RPE) was visualized as a uniform hexagonal array in nonlasered areas. On day 7 after laser burn, well-defined isolectin-B4 labeled CNV networks were shown within the burn spots of the 2 control groups. The inhibitory effects of the 3 siRNAs on CNV formation were statistically significant as compared to the 2 control groups. Compared to the control groups, the ocular expression of VEGF mRNA was decreased significantly in the 3 siRNA treated groups. The areas of CNV correlated with the expression of VEGF mRNA. Anti-VEGFA/VEGFR2 or non-specific siRNA can inhibit CNV and attenuate VEGF mRNA expression in a laser-induced mouse model of CNV. We conclude that the siRNAs may be an option for treating patients with exudative AMD, and more studies are needed to test the possible side-effects of the treatment.

Brivanib, a multitargeted small‐molecule tyrosine kinase inhibitor, suppresses laser‐induced CNV in a mouse model of neovascular AMD

Efficacy of Lenvatinib, a Multitargeted Tyrosine Kinase Inhibitor, on Laser-Induced CNV Mouse Model of Neovascular AMD.

Vascular Endothelial Growth Factor Receptor 2 Antibody, BC001, Attenuates Laser-Induced Choroidal Neovascularization in Rhesus Monkeys (Macaca mulatta)

Cabozantinib, a Multityrosine Kinase Inhibitor of MET and VEGF Receptors Which Suppresses Mouse Laser-Induced Choroidal Neovascularization.

Multityrosine Kinase Inhibitors Alleviate Laser-Induced Choroidal Neovascularization in Non-Human Primates: A Novel Therapy for Diabetic Retinopathy and Age-Related Macular Degeneration

Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA

Effects of Topic Delivery of an Inhibitor of Serine Racemase on Laser-Induced Choroidal Vasculopathy

Suppression of Pathological Ocular Neovascularization by a Small Molecular Multi-Targeting Kinase Inhibitor, DCZ19903

Repurposing Bortezomib for Choroidal Neovascularization Treatment Via Antagonizing VEGF-A and PDGF-D Mediated Signaling.

Stable Inhibition of Choroidal Neovascularization by Adeno-Associated Virus 2/8-Vectored Bispecific Molecules

Targeting of Junctional Adhesion Molecule-C Inhibits Experimental Choroidal Neovascularization

Targeted Long-term Noninvasive Treatment of Choroidal Neovascularization by Biodegradable Nanoparticles

DCZ19931, a novel multi-targeting kinase inhibitor, inhibits ocular neovascularization

Emerging Co-Assembled and Sustained Released Natural Medicinal Nanoparticles for Multitarget Therapy of Choroidal Neovascularization

Multimodal imaging and electroretinography highlights the role of VEGF in the laser-induced subretinal fibrosis of monkey

Intravitreal Ets1 siRNA alleviates choroidal neovascularization in a mouse model of age-related macular degeneration

Intravitreal injection of EV11, a novel aryl ketone amide, inhibits choroidal neovascularization via AKT/ERK1/2 pathway

Intravenous injection of l-aspartic acid β-hydroxamate attenuates choroidal neovascularization via anti-VEGF and anti-inflammation.

APRPG-modified Nanoliposome Loaded with Mir-146A-5p Inhibitor Suppressed Choroidal Neovascularization by Targeting Endothelial Cells.

A Novel Retinoic Acid Drug, EYE-502, Inhibits Choroidal Neovascularization by Targeting Endothelial Cells and Pericytes

Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy